Crossmark

A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-specific clinical success rates

Crossref DOI link: https://doi.org/10.1186/S13731-019-0111-1

Published: 2020-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

Authors

Dando, Jonathan http://orcid.org/0000-0002-1509-5386
Lebmeier, Maximilian http://orcid.org/0000-0002-5343-0122
License Information

Text and Data Mining valid from 2020-01-09
More Information

Article History

Received: 1 October 2018

Accepted: 26 November 2019

First Online: 9 January 2020

Competing interests

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below